According to the research report titled ‘Global Antiviral Combination Therapies Market Size study, by Drug Combination (NRTI/NNRTI, Integrase Inhibitor/NRTI, NRTI, NRTI/Protease Inhibitor, Others) by Type (Branded, Generic) by Indication (HIV, Hepatitis, Others) by Route of Administration (Oral, Intravenous) and Regional Forecasts 2020-2027’, available with Market Study Report, global antiviral combination therapies market was valued at USD 40.4 billion in 2019 and is projected to record a substantial growth during 2020-2027.
 

Increasing investment in R&D for the development of combination medications that help in fighting antiviral resistance, rising pervasiveness of viral diseases, and mounting demand for antiviral combinations for the treatment of HIV are key factors stimulating global antiviral combination therapies market growth.
 

For those unfamiliar, antiviral combination therapies are medications made using two or more drugs to treat a variety of viral diseases, such as HIV, hepatitis B, and hepatitis C. The combination antiretroviral treatment helps to prevent the virus from making several copies of itself in the body.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/3029623/
 

Moreover, the triple combination of lopinavir-ritonavir and infection beta-1b have demonstrated great potential in treatment of COVID-19. Historical results of the lopinavir-ritonavir-ribavirin combination, which was successful in lowering mortality and morbidity rates of then serious acute respiratory syndrome, are being referred to by researchers in healthcare organizations and businesses.
 

In addition, established players are concentrating on strategies such as product launches, innovations, and mergers & acquisitions to ensure profitability, further swaying worldwide antiviral combination therapies market dynamics.
 

For instance, Boehringer Ingelheim, based in Germany, announced in April 2018 that it will invest USD 75 million in a high-tech building at its Lyon Porte-des-Alpes facility in France to fulfill the rising demand for avian vaccines around the world.
 

On the downside, strict government norms are anticipated to hamper worldwide antiviral combination therapies industry expansion over the forecast period.
 

Citing the regional terrain, North America presently holds a major portion of global antiviral combination therapies market share, creditable to increasing research & development of combination drugs for COVID-19 treatment, growing usage for treating viral diseases, and presence of major players in the region.
 

Major contenders in global antiviral combination therapies market sphere are Merck & Co. Inc., Mylan N.V., Cipla Inc., Janssen Global Services LLC, Bristol-Myers Squibb Company, AbbVie Inc., Gilead Sciences Inc., GlaxoSmithKline plc, and Celltrion Inc.